Researchers recently reported multidrug delivery using nanoparticles to mediate resistance in relapsing cancers and to improve triple-negative breast cancer treatment efficacy. Other recent approaches have included layer-by-layer siRNA and doxorubicin delivery for breast cancer therapy, simultaneous loading of small interfering RNA (siRNA) and tumor-penetrating peptides against ovarian cancer, as well as sequential administration of multiple types of nanoparticles for pancreatic cancer treatment. These exciting approaches have served as a foundation for the next phase of cancer nanomedicine in the clinic—the rational design of nanomaterial-drug combinations.
Until more nanoparticles are validated in the clinic, however, the impact that nanomedicine may have on cancer treatment has yet to be fully realized. In order for chemotherapies modified using nanotechnology to profoundly change hematological and oncological practice, the application of engineered nanomedicines must be paired with emerging strategies to rationally design nanotherapeutic combinations. This is critical because combinatorial therapy is an efficient way to simultaneously address the barriers to treatment success, and it is widely used in treating cancer and infectious diseases
Read the full, original story: Fighting Cancer with Nanomedicine